Zealand Pharma A/S (OTCMKTS:ZLDPF) Stock Falls 15.7% – Should You Sell?

Zealand Pharma A/S (OTCMKTS:ZLDPF)’s stock price traded down 15.7% during mid-day trading on Friday. The stock traded as low as $36.80 and last traded at $36.80. 500 shares traded hands during trading, a decline of 81% from the average daily volume of 2,647 shares. The stock had previously closed at $43.66.

Analyst Upgrades and Downgrades

Several research firms have recently commented on ZLDPF. Berenberg Bank downgraded Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, June 17th. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating on shares of Zealand Pharma A/S in a research note on Thursday, June 4th. Jefferies Financial Group lowered shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a report on Monday, July 13th. Zacks Research upgraded shares of Zealand Pharma A/S from a “strong sell” rating to a “hold” rating in a research note on Friday, September 11th. Finally, Wolfe Research downgraded shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a report on Thursday, June 11th. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and nine have issued a Hold rating to the stock. According to MarketBeat.com, Zealand Pharma A/S currently has a consensus rating of “Hold”.

Zealand Pharma A/S Price Performance

The firm has a fifty day simple moving average of $46.78 and a two-hundred day simple moving average of $46.36. The firm has a market cap of $2.86 billion, a PE ratio of 6.63 and a beta of 0.95. The company has a debt-to-equity ratio of 0.02, a quick ratio of 13.98 and a current ratio of 13.98.

About Zealand Pharma A/S

Zealand Pharma A/S is a biotechnology company headquartered in Denmark that discovers, develops and commercializes peptide-based medicines. Its research focuses primarily on metabolic and gastrointestinal diseases, including obesity, diabetes and rare disorders. The company develops therapies designed to address significant unmet medical needs through its expertise in peptide chemistry and drug delivery.

Zealand’s marketed product portfolio includes Zegalogue (dasiglucagon), an emergency treatment for severe hypoglycemia in people with diabetes.